JPWO2020212874A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020212874A5
JPWO2020212874A5 JP2021561000A JP2021561000A JPWO2020212874A5 JP WO2020212874 A5 JPWO2020212874 A5 JP WO2020212874A5 JP 2021561000 A JP2021561000 A JP 2021561000A JP 2021561000 A JP2021561000 A JP 2021561000A JP WO2020212874 A5 JPWO2020212874 A5 JP WO2020212874A5
Authority
JP
Japan
Prior art keywords
antibody
composition
week
pharmaceutical composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021561000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529266A (ja
JP7628962B2 (ja
JP2022529266A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/053565 external-priority patent/WO2020212874A1/en
Publication of JP2022529266A publication Critical patent/JP2022529266A/ja
Publication of JPWO2020212874A5 publication Critical patent/JPWO2020212874A5/ja
Publication of JP2022529266A5 publication Critical patent/JP2022529266A5/ja
Priority to JP2025013906A priority Critical patent/JP2025069284A/ja
Application granted granted Critical
Publication of JP7628962B2 publication Critical patent/JP7628962B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021561000A 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法 Active JP7628962B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025013906A JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN201921015050 2019-04-15
IN202021004422 2020-01-31
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025013906A Division JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Publications (4)

Publication Number Publication Date
JP2022529266A JP2022529266A (ja) 2022-06-20
JPWO2020212874A5 true JPWO2020212874A5 (https=) 2023-04-20
JP2022529266A5 JP2022529266A5 (https=) 2023-04-20
JP7628962B2 JP7628962B2 (ja) 2025-02-12

Family

ID=72837755

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561000A Active JP7628962B2 (ja) 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法
JP2025013906A Pending JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025013906A Pending JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Country Status (16)

Country Link
US (1) US20220298233A1 (https=)
EP (1) EP3956357A4 (https=)
JP (2) JP7628962B2 (https=)
KR (1) KR20210140780A (https=)
CN (1) CN113825768A (https=)
AU (1) AU2020259375A1 (https=)
BR (1) BR112021020612A2 (https=)
CA (1) CA3143604A1 (https=)
IL (1) IL287213A (https=)
JO (1) JOP20210279A1 (https=)
MA (1) MA55729A (https=)
MX (1) MX2021012652A (https=)
MY (1) MY210310A (https=)
PH (1) PH12021552536A1 (https=)
SG (1) SG11202111056YA (https=)
WO (1) WO2020212874A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024323792A1 (en) * 2023-08-11 2026-03-12 Innovent Biologics (Suzhou) Co., Ltd. Method for treating plaque psoriasis wherein subject previously receiving biologic therapy for plaque psoriasis switches to using anti-il23p19 antibody
AU2024338774A1 (en) * 2023-09-07 2026-03-26 Innovent Biologics (Suzhou) Co., Ltd. Method for treating moderate and severe psoriasis using recombinant anti-il-23p19 antibody
WO2026069253A1 (en) * 2024-09-30 2026-04-02 Sun Pharmaceutical Industries Limited Long term safety of tildrakizumab in psoriatic arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
EP2007426A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
AR065420A1 (es) * 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
CA2734919C (en) * 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
ES2729603T3 (es) * 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Similar Documents

Publication Publication Date Title
US20240417455A1 (en) Treatment for rheumatoid arthritis
JP2024075713A5 (https=)
JP2025172841A5 (https=)
US20010018053A1 (en) Methods for treating disease states comprising administration of low levels of antibodies
JP2025102888A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2014114288A5 (https=)
JP2021523188A5 (https=)
JP2020535149A5 (https=)
JP2020502261A5 (https=)
JP2021514003A5 (https=)
JP2025069284A5 (https=)
JPWO2019177888A5 (https=)
JP2021523881A5 (https=)
WO2007119447A1 (ja) 関節リウマチの処置剤
JPWO2020212874A5 (https=)
JPWO2022190034A5 (https=)
JPWO2021195530A5 (https=)
CN115515978A (zh) 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体
WO2019027828A1 (en) DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES
JPWO2020245766A5 (https=)
TW202246329A (zh) 抗il-17抗體治療自體免疫性疾病和炎症的方法
Prous Annual update 2004/2005–treatment of respiratory disorders
JPWO2020245676A5 (https=)
JPWO2020128864A5 (https=)
JP2002521491A (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子